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custom made Cera PDA occluder (Lifetech Scientiﬁc, Shenzhen,
China). In the second setting, using the same hardware, a custom
made 30/28 mm Cera PDA occluder was positioned across the PDA. A
descending aortogram, done 15 minutes after positioning the device,
showed some ﬂow across the device.
A repeat angiogram, done 30 minutes later showed markedly
reduced ﬂow across the PDA. The device was released at this time,
under ﬂuoroscopic guidance.Echocardiography done next day showed no ﬂow across the PDA.
RESULTS Six patients with large PDA measuring 14-16 mm were taken
up for percutaneous device closure. After failed attempt with 24 mm
ASD device& 16 mm AGA PDA device in ﬁrst cases all four cases were
closed successfully with life tech 30/28 mm PDA device closure. In two
cases children between 12-14 yrs PDA device of 30/28 mm was too big
to obstruct aorta and was replaced with 24 mm muscular VSD device
successfully. Two patients have had follow up cath angio which
conﬁrmed low pa pressure & no obstruction of aorta or LPA.
CONCLUSION In selected cases of large PDA measuring 14-16 mm
1) PDA device with life tech 30/28 mm is successful (PDA device is
two times the size of PDA)
2) 30/28 mm PDA is too large for children of 12 years & below & it
results in obstruction of aorta
3) this is more cost effective simple than surgery
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BACKGROUND The ResoluteTM zotarolimus-eluting stent (R-ZES)
demonstrates favorable outcomes in the treatment of coronary lesions
across a range of patient and lesion complexity. However, limited
long-term data is available on the treatment of long lesions. The
RESOLUTE 38-mm substudy of the RESOLUTE Global Clinical Program
was prospectively designed to include patients requiring treatment of
de novo lesions in native coronary arteries with a 38-mm length
R-ZES.
METHODS The RESOLUTE 38-mm substudy includes patients from
the RESOLUTE US (R-US) and RESOLUTE Asia (R-Asia) prospective,
observational, nonrandomized, multicenter trials that enrolled pa-
tients from 29 sites across the United States (U.S.) and 17 sites across
Asia. Patients enrolled in these trials who received at least one 38-mm
R-ZES in a lesion 35 mm in length and reference vessel diameter of
3.0 to 4.2 mm with up to two lesions (in separate vessels) were
included in the 38-mm substudy. Target lesion failure (TLF) was
deﬁned as the composite of cardiac death (CD), target vessel
myocardial infarction (TV-MI), or clinically driven target lesion
revascularization (TLR). The RESOLUTE 38-mm substudy was a pre-
speciﬁed analysis; a post hoc analysis by geography (Asia vs. US) was
also conducted.
RESULTS A total of 223 patients (114 in R-US and 109 in R-Asia) were
enrolled. Mean lesion length was 25.2  8.8 mm (24.2  9.1 in R-US vs.
26.3  8.5 in R-Asia, p¼0.059). Compared with R-Asia patients, R-US
patients were older (65  10 mm vs. 57  10 mm, p<0.001), and more
likely to have diabetes mellitus (44% vs. 31%, p¼0.051) and insulin
dependent diabetes mellitus (15% vs. 6%, 0.021). Three-year follow-
up was available in 221 (99.1%) patients demonstrating a low inci-
dence of adverse clinical events (Figure, left). There was furthermore
no difference at 3 years in the rates of TLR, CD, or TV-MI between
R-Asia and R-US; however, TLF was lower in R-Asia (Figure, right).
CONCLUSION The 38-mm length R-ZES was associated with excellent
and sustained clinical outcomes during long-term follow-up. Patients
enrolled in Asia appeared to be less complex than those enrolled in
the U.S., but clinical events remained similar other than for TLF.
